Gestrinone是一种抗雌激素抗孕酮的19-去甲睾酮衍生物,可用以治疗某些雌激素依赖性疾患如良性乳腺肿物及子宫内膜异位症等。因其能使子宫退化主要用于治疗子宫肌瘤,但停药后有些病人出现反跳现象仍需手术治疗。为探求长期给药可能性和选择较好的给药途径,作者对100例子宫肌瘤妇女作了一次gestrinone治疗的前瞻性随机分组观察。A组41人,口服2.5mg每周三次,B组31人,口服5mg每周二次,C组28人,阴道用药5mg,于每周一、三、五给药。治疗前及治疗期间每3个月用超声图测量子宫体积,以数值大小评价疗效。子宫体积以子宫纵、横、前后径相乘再乘以参数0.45求 Gestrinone is an anti-estrogen anti-progesterone 19-nortestosterone derivative that can be used to treat certain estrogen-dependent disorders such as benign breast masses and endometriosis. Because of its ability to degenerate the uterus is mainly used for the treatment of uterine fibroids, but some patients after stopping the rebound phenomenon still need surgery. To explore the possibility of long-term dosing and to choose a better route of administration, the authors performed a prospective randomized study of 100 gestrinone-treated women with uterine fibroids. A group of 41 people, oral 2.5mg three times a week, B group of 31 people, oral 5mg twice a week, C group of 28 people, vaginal medication 5mg, on Monday, Wednesday and Friday administration. Uterine volume was measured with an ultrasound image every 3 months before treatment and during treatment, and the effect was evaluated by numerical values. Uterine volume to the uterus vertical and horizontal, before and after the multiplication multiplied by the parameter 0.45 seeking